AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15214959 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline plus rifampicin (200 mg/day plus 600 mg/day for 45 days)
Number of subjects: 29
Study 10737828 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-family group psychoeducation treatment
Number of subjects: 63
Study 10737828 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 63
Study 8889681 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.75% THC cigarette
Number of subjects: 6
Study 8889681 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.55% THC cigarette
Number of subjects: 6
Study 8889681 — intervention group
Group type: COMPARATOR
Intervention: Placebo cigarette
Number of subjects: 6
Study 1643800 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Insulin (HI)
Number of subjects: 10
Study 1643800 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine Insulin (PI)
Number of subjects: 10
Study 6332903 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 46
Study 6332903 — intervention group
Group type: COMPARATOR
Intervention: TENS at 100 Hz
Number of subjects: 46
Study 6332903 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS at 8 Hz
Number of subjects: 46
Study 6332903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 30486801 — intervention group
Group type: EXPERIMENTAL
Intervention: Four additional healthier options (compared to two healthier and two less healthy options)
Number of subjects: 1509
Study 30486801 — intervention group
Group type: EXPERIMENTAL
Intervention: Four additional less healthy options (compared to two healthier and two less healthy options)
Number of subjects: 1509
Study 30486801 — intervention group
Group type: COMPARATOR
Intervention: Two healthier and two less healthy options
Number of subjects: 1509
Study 28417196 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustaining rod
Number of subjects: 122
Study 28417196 — intervention group
Group type: COMPARATOR
Intervention: Rod-less protocol
Number of subjects: 122
Study 28417196 — intervention group
Group type: EXPERIMENTAL
Intervention: High BMI (>26)
Number of subjects: 122
Study 25758874 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (200 mg)
Number of subjects: 0
Study 25758874 — intervention group
Group type: COMPARATOR
Intervention: Levodopa-c (110 mg)
Number of subjects: 0
Study 23838349 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine 20 mg/m² on days 1 to 5 for up to 4 courses
Number of subjects: 406
Study 23838349 — intervention group
Group type: COMPARATOR
Intervention: Low-dose Ara-C (LDAC) 20 mg twice daily for 10 days every 6 weeks for up to 4 courses
Number of subjects: 406
Study 20492056 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat application (20-minute sessions every other day for four weeks)
Number of subjects: 46
Study 20492056 — intervention group
Group type: COMPARATOR
Intervention: Routine medication (control group)
Number of subjects: 46
Study 18782532 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinlong Capsule (TACE therapy plus Jinlong Capsule)
Number of subjects: 48
Study 18782532 — intervention group
Group type: COMPARATOR
Intervention: Control group (TACE therapy alone)
Number of subjects: 48
Study 16052202 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterweight programme intervention
Number of subjects: 1549
Study 16052202 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterweight programme intervention (completers)
Number of subjects: 1549
Study 12665497 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic right atrial stretch due to ASD
Number of subjects: 13
Study 12665497 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after ASD closure (8.3±5.6 months)
Number of subjects: 13
Study 12665497 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 13
Study 10825854 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Tartar Control Plus Whitening Fluoride dentifrice (test dentifrice)
Number of subjects: 79
Study 10825854 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice (non-tooth whitening dentifrice)
Number of subjects: 79
Study 7490386 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Incidental Training (FIT)
Number of subjects: 76
Study 7490386 — intervention group
Group type: COMPARATOR
Intervention: Prompted Voiding (PV)
Number of subjects: 76
Study 7490386 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (FIT and PV)
Number of subjects: 76
Study 2147775 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention programme aimed at improving personal control and social activation over 24 weeks
Number of subjects: 65
Study 2147775 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 65
Study 7014886 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil
Number of subjects: 72
Study 7014886 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil and levamisole
Number of subjects: 72
Study 7014886 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 72
Study 31793699 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider-derived option labels
Number of subjects: 1062
Study 31793699 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry-derived option labels
Number of subjects: 1062
Study 31793699 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific label set mentioned)
Number of subjects: 1062
Study 31793699 — intervention group
Group type: EXPERIMENTAL
Intervention: All option labels
Number of subjects: 1062
Study 30545562 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Rhinosinusitis Symptom Scale (PRSS)
Number of subjects: 258
Study 29187135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive LDKT education (n = 249) consisting of a 25-minute video and discussion with an educator.
Number of subjects: 499
Study 29187135 — intervention group
Group type: COMPARATOR
Intervention: Usual care education (n = 250).
Number of subjects: 499
Study 29187135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive LDKT education (n = 249) for patients without a potential living donor.
Number of subjects: 499
Study 29187135 — intervention group
Group type: COMPARATOR
Intervention: Usual care education (n = 250) for patients without a potential living donor.
Number of subjects: 499
Study 25910710 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention composed of speech sound practice and augmentative and alternative communication
Number of subjects: 10
Study 25910710 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 10
Study 23331339 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 71
Study 23331339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 21323779 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 840
Study 21323779 — intervention group
Group type: COMPARATOR
Intervention: Postal questionnaire
Number of subjects: 840
Study 21323779 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview and Postal questionnaire
Number of subjects: 840
Study 19476402 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 75 mg taken on two consecutive days each month (2CDM)
Number of subjects: 1229
Study 19476402 — intervention group
Group type: COMPARATOR
Intervention: Risedronate 5 mg taken once daily
Number of subjects: 1229
Study 19476402 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 75 mg 2CDM
Number of subjects: 1229
Study 19476402 — intervention group
Group type: COMPARATOR
Intervention: Risedronate 75 mg 2CDM and Risedronate 5 mg once daily
Number of subjects: 1229
Study 17969893 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhiling Capsule (ZLC)
Number of subjects: 400
Study 17969893 — intervention group
Group type: COMPARATOR
Intervention: Pingxiao Capsule (PXC)
Number of subjects: 400
Study 15110417 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive factors
Number of subjects: 10650
Study 15110417 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial factors
Number of subjects: 10650
Study 15110417 — intervention group
Group type: COMPARATOR
Intervention: SES (socioeconomic status)
Number of subjects: 10650
Study 11806862 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (2 mg administered by inhalator)
Number of subjects: 0
Study 11806862 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 9512232 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon catheter
Number of subjects: 61
Study 8874977 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg/day)
Number of subjects: 143
Study 8874977 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole (200 mg/day)
Number of subjects: 143
Study 8874977 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 143
Study 8874977 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole
Number of subjects: 143
Study 8874977 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 143
Study 2328750 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg metamizol sodium
Number of subjects: 15
Study 2328750 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg metamizol sodium
Number of subjects: 15
Study 2328750 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 mg metamizol sodium
Number of subjects: 15
Study 7307999 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (40 mg orally in delay‐action form and 5 mg sublingually)
Number of subjects: 16
Study 7307999 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg)
Number of subjects: 16
Study 7307999 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydralazine (75 mg)
Number of subjects: 16
Study 7307999 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (three times 20 mg)
Number of subjects: 16
Study 7307999 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (three times 2 mg)
Number of subjects: 16
Study 7307999 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydralazine (three times 75 mg)
Number of subjects: 16
Study 30994090 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine (9.0 × 10^5 sporozoites, three doses)
Number of subjects: 93
Study 30994090 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine (9.0 × 10^5 sporozoites, one dose)
Number of subjects: 93
Study 28554455 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletally anchored facemasks anchored with miniplates placed at the zygomatic buttress (Group 1)
Number of subjects: 30
Study 28554455 — intervention group
Group type: EXPERIMENTAL
Intervention: Class III elastics extending from infrazygomatic miniplates in the maxilla to symphyseal miniplates in the mandible (Group 2)
Number of subjects: 30
Study 28554455 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group (Group 3)
Number of subjects: 30
Study 25741795 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based guided self-help intervention
Number of subjects: 231
Study 25741795 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 231
Study 23098695 — intervention group
Group type: EXPERIMENTAL
Intervention: Penetrating needles
Number of subjects: 80
Study 23098695 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-touch placebo needles
Number of subjects: 80
Study 23098695 — intervention group
Group type: COMPARATOR
Intervention: No-touch control needles
Number of subjects: 80
Study 23098695 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall subjects' guesses
Number of subjects: 80
Study 21070456 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA injections
Number of subjects: 100
Study 21070456 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline injections
Number of subjects: 100
Study 18377608 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke from burnt leaves of Populus euphratica (Group A)
Number of subjects: 60
Study 18377608 — intervention group
Group type: COMPARATOR
Intervention: Conventional cryotherapy (Group B)
Number of subjects: 60
Study 16298237 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐ECD SPECT and memory scores
Number of subjects: 31
Study 16298237 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoperfusion pattern from 99mTc‐ECD SPECT
Number of subjects: 31
Study 12670465 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 0
Study 12670465 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Number of subjects: 0
Study 12670465 — intervention group
Group type: EXPERIMENTAL
Intervention: Purine analogues (2-deoxycoformycin and 2-chlorodeoxyadenosine)
Number of subjects: 0
Study 10914804 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydioxanon barrier (test)
Number of subjects: 21
Study 10914804 — intervention group
Group type: COMPARATOR
Intervention: Polylactide acetyltributyl citrate (control)
Number of subjects: 21
Study 8678514 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU 10 mg/kg/24 hrs c.i.v. x 24 days (arm A, n = 25)
Number of subjects: 70
Study 8678514 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU 20 mg/kg/24 hrs c.i.v. x 4 days/w x 3 courses (arm B, n = 16)
Number of subjects: 70
Study 8678514 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU 30 mg/kg/24 hrs c.i.v. x 2 days/w x 4 courses (arm C, n = 25)
Number of subjects: 70
Study 8678514 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified arm B (4 days-on, 6 days-off)
Number of subjects: 70
Study 8678514 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 70
Study 1769473 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 76
Study 1769473 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic Sclerotherapy
Number of subjects: 76
Study 7043340 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 49
Study 7043340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 30666732 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4 50% solution (MSS at 40 mg/kg BW)
Number of subjects: 6
Study 30666732 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose solution (DS; control solution at 2 mL/kg body weight)
Number of subjects: 6
Study 27521509 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (cycling and resistance training) 3 times per week for 12 weeks
Number of subjects: 24
Study 27521509 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 24
Study 26296190 — intervention group
Group type: EXPERIMENTAL
Intervention: Clavicle brace
Number of subjects: 30
Study 26296190 — intervention group
Group type: COMPARATOR
Intervention: Control group (no brace)
Number of subjects: 30
Study 24603102 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (50 mg daily)
Number of subjects: 279
Study 24603102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 23181920 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation and peer social support
Number of subjects: 1421
Study 23181920 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation and parent social support
Number of subjects: 1421
Study 19483659 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-534 vaccine (10 median tissue culture infectious dose50)
Number of subjects: 120
Study 19483659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 17634081 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch test with a dilution series of 19 concentrations, duration up to 21 days
Number of subjects: 20
Study 17634081 — intervention group
Group type: COMPARATOR
Intervention: Repeated open application test (ROAT) with a dilution series of three concentrations, duration up to 21 days
Number of subjects: 20
Study 15353095 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethical Will (EW)
Number of subjects: 24
Study 15353095 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 11286826 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (CT) with cisplatin 60 mg/m² and epirubicin 110 mg/m² followed by radiotherapy (RT)
Number of subjects: 179
Study 11286826 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 179
Study 11286826 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (CT) with cisplatin and epirubicin
Number of subjects: 179
Study 9885030 — intervention group
Group type: EXPERIMENTAL
Intervention: Three months intensive training
Number of subjects: 90
Study 9885030 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise
Number of subjects: 90
Study 9885030 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 8011248 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet at a dose of 60 mg/kg every 8 h for 14 days followed by maintenance doses of 60 or 90 mg/kg/day.
Number of subjects: 156
Study 8011248 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet at a maintenance dose of 120 mg/kg/day.
Number of subjects: 156
Study 8011248 — intervention group
Group type: COMPARATOR
Intervention: Foscarnet therapy compared to historic controls who terminated ganciclovir therapy.
Number of subjects: 156
Study 3192364 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin combined with decongestive nose drops
Number of subjects: 141
Study 3192364 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage of the maxillary sinus
Number of subjects: 141
Study 3192364 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amoxicillin and drainage
Number of subjects: 141
Study 3192364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 28482829 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery-oriented practice training intervention for specialist mental health services staff
Number of subjects: 756
Study 28482829 — intervention group
Group type: COMPARATOR
Intervention: Control group (services where staff have not yet received the intervention)
Number of subjects: 756
Study 26168365 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness in Motion (MIM) - a Mindfulness Based Intervention (MBI) delivered onsite for 1 hr/week for 8 weeks, including group sessions with gentle yoga stretches and relaxing music.
Number of subjects: 0
Study 26168365 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness in Motion (MIM) - a Mindfulness Based Intervention (MBI) delivered onsite for 1 hr/week for 8 weeks.
Number of subjects: 0
Study 26168365 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (C)
Number of subjects: 0
Study 23877228 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous exercise programme
Number of subjects: 21
Study 23877228 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval exercise programme
Number of subjects: 21
Study 23877228 — intervention group
Group type: COMPARATOR
Intervention: Both exercise programmes
Number of subjects: 21
Study 21755342 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg aminophylline
Number of subjects: 150
Study 21755342 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg aminophylline
Number of subjects: 150
Study 21755342 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg aminophylline
Number of subjects: 150
Study 21755342 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg aminophylline
Number of subjects: 150
Study 21755342 — intervention group
Group type: EXPERIMENTAL
Intervention: aminophylline (2, 3, 4, 5 mg/kg)
Number of subjects: 150
Study 21755342 — intervention group
Group type: EXPERIMENTAL
Intervention: aminophylline (4, 5 mg/kg)
Number of subjects: 150
Study 18463672 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril-HCT (20 mg q.d.)
Number of subjects: 354
Study 18463672 — intervention group
Group type: COMPARATOR
Intervention: HCT monotherapy
Number of subjects: 354
Study 18463672 — intervention group
Group type: COMPARATOR
Intervention: Ramipril monotherapy
Number of subjects: 354
Study 16871533 — intervention group
Group type: EXPERIMENTAL
Intervention: Gout
Number of subjects: 12866
Study 16871533 — intervention group
Group type: COMPARATOR
Intervention: No gout
Number of subjects: 12866
Study 16871533 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperuricemia
Number of subjects: 12866
Study 12594698 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine (600 mg twice a day 24 hr before and the day of cardiac catheterization)
Number of subjects: 179
Study 12594698 — intervention group
Group type: COMPARATOR
Intervention: Control (intravenous hydration alone)
Number of subjects: 179
Study 12594698 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Number of subjects: 179
Study 12594698 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 179
Study 10962116 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CAD (n=355)
Number of subjects: 355
Study 10962116 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CAD with type-2 DM (n=101)
Number of subjects: 355
Study 10962116 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (n=100)
Number of subjects: 355
Study 9549283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (150-200 mg/day)
Number of subjects: 16
Study 9549283 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (prothrombin time controlled to 15-25%)
Number of subjects: 16
Study 9549283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 16
Study 9549283 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 16
Study 8221800 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP (50 pmol.min‐1)
Number of subjects: 12
Study 3708124 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal formulations
Number of subjects: 26
Study 3708124 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered products
Number of subjects: 26
Study 3708124 — intervention group
Group type: COMPARATOR
Intervention: All formulations
Number of subjects: 26
Study 3708124 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated ASA formulations
Number of subjects: 26
Study 30229462 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 40
Study 30229462 — intervention group
Group type: EXPERIMENTAL
Intervention: Armolipid Plus® (combined lipid-lowering nutraceutical)
Number of subjects: 40